Background
Methods
Patient population
Reagent
Enzyme-linked immunosorbent assay (ELISA)
Immunohistochemical (IHC) staining
Statistical Analysis
Results
The levels of plasma sPLA2-IIa are increased in lung cancer patients
BNLCC-Lung cancer
| 96 | |
M/F | 37/59 | |
Mean age year (range) | 64 (41~88) | |
NSCLC | 93 | |
Adenocarcinoma | 54 | |
Squamous carcinoma | 21 | |
Other NSCLC | 18 | |
SCLC | 3 | |
Stage | ||
I | 44 | |
II | 18 | |
III+IV | 4 | |
Blooddraw before resection | 96 | |
Blooddraw after resection | 0 | |
BNLCC-benign SPN
| 29 | |
M/F | 15/14 | |
Mean age year (range) | 56 (31~81) | |
Blooddraw before resection | 29 | |
Blooddraw after resection | 0 | |
GELCC-Lung cancer
| 44 | |
M/F | 18/26 | |
Mean age year (range) | 61 (47~70) | |
Healthy donor
| 20 | |
Mean age year (range) | 49 (24~65) |
Sample | sPLA2-IIa (pg/ml) | Diagnosis |
---|---|---|
1 | 1039.2 | 0.9 cm nodule and heavy smoker |
2 | 1589.2 | 1.3 × 1.4 × 1.1 cm subpleural nodule, necrotizing granuloma |
3 | 480.83 | Nodule 2 cm |
4 |
8980.8
| Necrotizing granulomatous |
5 | 1030.8 | Nonnecrotizing granulomas |
6 | 1105.8 | Abscess colonized with fungal hyphae |
7 |
3680.8
| Nodule with organizing pneumonia pattern of lung injury |
8 | 922.5 | Caseating granulomas with emphysematous changes |
9 | 797.5 | Nodules of caseating granulomas |
10 | 2372.5 | Necrotizing granuloma with fungal organisms |
11 | 1789.2 | Peribronchial tumorlet-2 mm and focal parenchymal fibrosis |
12 | 580.83 | Necrotizing granuloma with fungal organisms |
13 | 2305.8 | Necrotizing granuloma (2 × 1.7 × 1.3 cm) |
14 | 872.5 | Broncial and broncheolar ectasis with fibrosis and chronic inflammation c/w bronchiectasis |
15 |
2714.2
| Bronchiolitis obliterans organizing pneumonia |
16 | 714.17 | Focal fibrosis and chronic inflammation and reactive pneumocyte hyperplasia |
17 | 2105.8 | Caseating granulomas with fungal elements |
18 |
2422.17
| Myolipomatous polyp |
19 | 1226.52 | Active granulomatous inflammation and possible sarcoidosis |
20 | 2217.83 | Neurofibroma, 4.5 × 3.5 cm |
21 | 1804.78 | Active non-caseating granulomas |
22 | 430.87 | Necrotizing granuloma with fungal organisms |
23 |
3878.7
| Caseating necrotizing granulomas with fungal elements |
24 | 835.22 | Non-caseating granulomas with fungal elements |
25 | 572.5 | Necrotizing granulomatous inflammation with fungal organisms consistent with Aspergillus |
26 | 1553.75 | Necrotizing granulomas with fungal yeast forms consistent with Histoplasma |
27 | 816.25 | Organizing suppurative bronchopneumonia with pleural adhesions |
28 | 1328.75 | Presented with sTable lung nodule |
29 | 1228.13 | necrotizing granuloma and Langerhans' cell histiocytosis |
Plasma sPLA2-IIa | < 2.4 ng/ml | > 2.4 ng/ml | Total case# | %Senstivity | %Specificity |
---|---|---|---|---|---|
Table 3a: Determination of plasma sPLA2-IIa to predict lung cancer by ROC analysis. | |||||
BNLCC lung cancer vs. benign SPN
| |||||
Benign SPN | 24 | 5 | 29 |
86
| |
Lung cancer | 50 | 46 | 96 |
48
| |
Stage 1 lung cancer | 24 | 20 | 44 |
45
| |
Stage 2 lung cancer | 6 | 12 | 18 |
67
| |
GELCC lung cancer vs. benign SPN
| |||||
Lung cancer | 16 | 28 | 44 |
64
| |
Table 3b: Combined sPLA2-IIa, CEA, and Cyfra21.1 blood tests increase the sentisitivity
to predict lung cancer. | |||||
sPLA2-IIa
|
< 2.4 ng/ml
|
> 2.4 ng/ml
| |||
CEA
|
< 6.0 ng/ml
|
> 6.0 ng/ml
|
Total case#
|
%Senstivity
|
%Specificity
|
Cyfra21.1
|
< 3.3 ng/ml
|
> 3.3 ng/ml
| |||
BNLCC lung cancer vs. benign SPN
| |||||
Benign SPN | 22 | 7 | 29 |
76
| |
Lung cancer | 36 | 60 | 96 |
63
| |
Stage 1 lung cancer | 18 | 26 | 44 |
59
| |
Stage 2 lung cancer | 5 | 13 | 18 |
72
| |
CEA
|
< 6.0 ng/ml
|
> 6.0 ng/ml
|
Total case#
|
%Senstivity
|
%Specificity
|
BNLCC lung cancer vs. benign SPN
| |||||
Benign SPN | 28 | 1 | 29 |
97
| |
Lung cancer | 77 | 19 | 96 |
20
| |
Cyfra21.1
|
< 3.3 ng/ml
|
> 3.3 ng/ml
|
Total case#
|
%Senstivity
|
%Specificity
|
BNLCC lung cancer vs. benign SPN
| |||||
Benign SPN | 27 | 2 | 29 |
93
| |
Lung cancer | 83 | 13 | 96 |
14
|